12.21.15
Japanese drug giant Eisai has entered into a business acquisition agreement with Alfresa Holdings Corporation concerning the splitting off of Eisai's consolidated pharmaceutical manufacturing and marketing subsidiary Sannova. The effective date of the split is scheduled to be March 31, 2016.
Sannova produces a variety of formulations such as granules, powders, tablets, liquids, ointments, creams and lotions of prescription pharmaceuticals, generics, over the counter pharmaceuticals and quasi-drugs.
Alfresa Holdings says it is working to strengthen its pharmaceutical contract manufacturing business centered on its wholly-owned subsidiary Alfresa Pharma Corporation.
Eisai says it will continue to commission the new company who will succeed the business of Sannova via absorption-type split to manufacture Eisai Group products currently manufactured by Sannova, and maintain a cooperative relationship with this new company.
Sannova produces a variety of formulations such as granules, powders, tablets, liquids, ointments, creams and lotions of prescription pharmaceuticals, generics, over the counter pharmaceuticals and quasi-drugs.
Alfresa Holdings says it is working to strengthen its pharmaceutical contract manufacturing business centered on its wholly-owned subsidiary Alfresa Pharma Corporation.
Eisai says it will continue to commission the new company who will succeed the business of Sannova via absorption-type split to manufacture Eisai Group products currently manufactured by Sannova, and maintain a cooperative relationship with this new company.